GO:2000119 negative regulation of sodium-dependent phosphate transport: Phosphate Homeostasis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000119 describes any process that stops, prevents, or reduces the frequency, rate or extent of sodium-dependent phosphate transport, a key mechanism in phosphate homeostasis.
• The term is a biological process and is essential for understanding how cells and organisms maintain inorganic phosphate balance.
• Major proteins involved include the sodium-dependent phosphate cotransporters SLC34A1 (NaPi-IIa), SLC34A2 (NaPi-IIb), SLC34A3 (NaPi-IIc), and SLC20A1/2 (PiT-1/2), as well as regulatory factors like ezrin, PTH, FGF23, and Klotho.
• Dysregulation of this process is linked to hyperphosphatemia, chronic kidney disease, tumor calcification, and cancer progression, making it a therapeutic target.
• Research tools include knockout and knock-in cell models, RNA-seq, proteomics, and imaging to dissect the regulatory network.
• EDITGENE provides CRISPR-based services to study genes involved in negative regulation of sodium-dependent phosphate transport, from KO to overexpression models.
Description
Sodium-dependent phosphate transport is a fundamental process for maintaining inorganic phosphate (Pi) homeostasis in mammals, and its negative regulation ensures that Pi levels do not become excessive, which could lead to pathological calcification and metabolic disorders. The Gene Ontology term GO:2000119, negative regulation of sodium-dependent phosphate transport, encompasses any process that stops, prevents, or reduces the frequency, rate or extent of sodium-dependent phosphate transport. This regulation is critical in tissues such as the kidney, intestine, and bone, where Pi uptake must be tightly controlled. Researchers study this term to understand how hormones like parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) modulate transporter activity and abundance, and how disruptions contribute to diseases like chronic kidney disease and cancer. The term is also relevant for drug development, as modulating phosphate transport can influence mineralization and tumor growth.
negative regulation of sodium-dependent phosphate transport At A Glance
| GO ID | GO:2000119 |
|---|---|
| GO term | negative regulation of sodium-dependent phosphate transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Downregulation of sodium-dependent phosphate transport to maintain phosphate homeostasis |
| Related transporters | SLC34A1 (NaPi-IIa), SLC34A2 (NaPi-IIb), SLC34A3 (NaPi-IIc), SLC20A1 (PiT-1), SLC20A2 (PiT-2) |
| Key regulators | PTH, FGF23, Klotho, ezrin, membrane microdomains |
| Associated diseases | Hyperphosphatemia, chronic kidney disease, tumor calcification, bladder cancer |
| Research methods | Knockout/knock-in models, RNA-seq, proteomics, imaging, transport assays |
What Is GO:2000119?
GO:2000119 is defined as any process that stops, prevents, or reduces the frequency, rate or extent of sodium-dependent phosphate transport. In other words, it includes molecular events that downregulate the movement of phosphate ions into cells via sodium-coupled transporters, either by decreasing transporter activity, promoting their internalization and degradation, or reducing their expression.
Why Is negative regulation of sodium-dependent phosphate transport Important in Cell Biology?
Negative regulation of sodium-dependent phosphate transport is vital for preventing phosphate overload, which can cause vascular calcification, bone disorders, and renal failure. It is a key mechanism through which hormones and dietary factors adjust Pi absorption to match physiological needs, and its dysregulation is implicated in a range of diseases from chronic kidney disease to cancer. Understanding this process provides insights into therapeutic strategies for managing phosphate-related pathologies.
• Maintains phosphate homeostasis by preventing excessive Pi uptake in the kidney and intestine.
• Mediates hormonal control of Pi transport by PTH and FGF23-Klotho signaling.
• Involved in bone mineralization and osteoblast function, with implications for osteoporosis and vascular calcification.
• Dysregulated in chronic kidney disease, leading to hyperphosphatemia and cardiovascular complications.
• Plays a role in cancer biology, as SLC34A2 overexpression is linked to bladder cancer progression.
• Target for drugs like tenofovir disoproxil fumarate, which suppresses phosphate transporter expression in osteoblasts.
• Provides a model for studying membrane trafficking and protein phosphorylation in transport regulation.
• Essential for understanding dietary phosphate absorption and its impact on health.
• Relevant to genetic disorders of phosphate wasting or retention.
• Offers opportunities for CRISPR-based functional genomics to identify novel regulators.
What Happens During negative regulation of sodium-dependent phosphate transport?
Hormonal Signaling Initiates the Response
In simple terms: Hormones like PTH and FGF23 act as signals that tell cells to reduce phosphate uptake.
Negative regulation of sodium-dependent phosphate transport often begins with hormonal signals. Parathyroid hormone (PTH) binds to its receptor on renal proximal tubular cells, triggering a signaling cascade that leads to the internalization of sodium-dependent phosphate transporters such as NaPi-IIa (SLC34A1) from the apical membrane. Similarly, FGF23, produced by osteocytes, acts on the kidney to reduce phosphate reabsorption by downregulating NaPi-IIa and NaPi-IIc, an effect that requires the co-receptor Klotho. These hormonal pathways are central to maintaining phosphate balance in response to dietary and metabolic changes.
Post-Translational Modifications of Transporters
In simple terms: Chemical tags added to transporter proteins can change their activity or location.
Phosphorylation and other post-translational modifications play a key role in regulating sodium-dependent phosphate transporters. For example, serine 249 of ezrin, a cytoskeletal linker protein, is phosphorylated in response to PTH, and this modification is involved in the downregulation of NaPi-IIa activity in renal proximal tubular cells. Ezrin interacts with the transporter and helps orchestrate its removal from the membrane. Additionally, membrane microdomains (lipid rafts) are important for PTH-mediated downregulation of NaPi-IIa, as disruption of these domains affects transporter internalization.
Endocytosis and Degradation of Transporters
In simple terms: Transporters are pulled into the cell and broken down, reducing their numbers on the surface.
Once signaled, sodium-dependent phosphate transporters are removed from the plasma membrane via endocytosis and targeted for degradation in lysosomes. This process reduces the number of active transporters available for phosphate uptake. Studies in opossum kidney cells show that PTH induces the internalization of NaPi-IIa, and this requires intact membrane microdomains. The reduction in transporter abundance directly lowers sodium-dependent phosphate transport capacity, achieving negative regulation.
Transcriptional and Post-Transcriptional Control
In simple terms: Cells can also make less of the transporter protein by turning down gene expression.
In addition to rapid endocytic regulation, negative regulation can occur at the level of gene expression. Tenofovir disoproxil fumarate, an antiretroviral prodrug, suppresses the expression of type II and type III sodium-dependent phosphate transporters in primary human osteoblasts, leading to reduced mineralization. This suggests that transcriptional or post-transcriptional mechanisms can downregulate transporter levels under certain conditions. Alternative splicing of renal transporters also contributes to diversity and regulation of phosphate transport.
Integration with Systemic Phosphate Homeostasis
In simple terms: The whole body works together to keep phosphate levels just right.
Negative regulation of sodium-dependent phosphate transport is integrated with systemic phosphate homeostasis through the bone-kidney axis. FGF23 and Klotho coordinate to reduce renal phosphate reabsorption and inhibit vitamin D activation, thereby lowering serum phosphate. Dietary phosphorus intake also modulates this process, with high phosphate diets affecting transporter expression and activity. This multi-organ communication ensures that phosphate levels remain within a narrow physiological range.
Key Genes Involved in GO:2000119 negative regulation of sodium-dependent phosphate transport
The following genes and proteins are central to the negative regulation of sodium-dependent phosphate transport, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC34A1 (NaPi-IIa) | Renal sodium-dependent phosphate cotransporter; target of PTH and FGF23 downregulation | Key mediator of renal phosphate reabsorption; knockout models show hyperphosphatemia |
| SLC34A2 (NaPi-IIb) | Intestinal and other tissue sodium-dependent phosphate cotransporter | Overexpression linked to bladder cancer; suppression reduces tumor growth |
| SLC34A3 (NaPi-IIc) | Renal sodium-dependent phosphate cotransporter | Mutations cause hereditary hypophosphatemic rickets with hypercalciuria |
| SLC20A1 (PiT-1) | Type III sodium-dependent phosphate transporter | Expressed in osteoblasts; downregulated by tenofovir |
| SLC20A2 (PiT-2) | Type III sodium-dependent phosphate transporter | Expressed in osteoblasts; downregulated by tenofovir |
| PTH | Parathyroid hormone; triggers downregulation of NaPi-IIa | Central regulator of phosphate homeostasis; used to study endocytosis |
| FGF23 | Fibroblast growth factor 23; reduces renal phosphate reabsorption | Key hormone in phosphate homeostasis; requires Klotho |
| Klotho | Co-receptor for FGF23 | Essential for FGF23 signaling; knockout mice exhibit hyperphosphatemia |
| Ezrin | Cytoskeletal linker protein; phosphorylation at S249 regulates NaPi-IIa | Involved in PTH-mediated downregulation; point mutation studies |
| c-Myc | Transcription factor; downstream of SLC34A2 | SLC34A2 depletion decreases c-Myc expression, affecting tumor growth |
| Tenofovir | Antiretroviral prodrug; suppresses phosphate transporter expression | Used to study drug-induced downregulation of transporters |
| Dietary phosphorus | Nutritional factor affecting transporter expression | High phosphate diet alters NaPi-IIa abundance |
| Membrane microdomains | Lipid rafts; required for PTH-mediated downregulation | Disruption affects NaPi-IIa internalization |
| Vitamin D | Regulates phosphate homeostasis | Interacts with FGF23/Klotho system |
| Osteoblasts | Bone-forming cells; express PiT-1 and PiT-2 | Model for studying mineralization and transporter regulation |
| Renal proximal tubule cells | Site of NaPi-IIa expression and regulation | Primary model for PTH-mediated downregulation |
| Cholangiocytes | Liver cells expressing sodium-phosphate cotransporters | Studied for phosphate transport in liver |
| Hepatocytes | Liver cells with sodium-phosphate cotransporters | Localization of transporters in liver |
How Is negative regulation of sodium-dependent phosphate transport Regulated?
The negative regulation of sodium-dependent phosphate transport is primarily controlled by hormonal signals, especially PTH and FGF23-Klotho, which respond to serum phosphate and vitamin D levels. PTH rapidly induces endocytosis of NaPi-IIa via phosphorylation of ezrin and involvement of membrane microdomains. FGF23, acting through Klotho, reduces the abundance of NaPi-IIa and NaPi-IIc in the kidney. Additionally, dietary phosphate intake modulates transporter expression, with high phosphate diets suppressing NaPi-IIa. Other factors, such as tenofovir, can directly suppress transporter expression in osteoblasts. These regulatory mechanisms ensure tight control of phosphate homeostasis.
negative regulation of sodium-dependent phosphate transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC34A1 | Hyperphosphatemia, renal phosphate wasting | Knockout mouse, renal proximal tubule cell lines |
| SLC34A2 | Bladder cancer, tumor growth | Knockdown/overexpression in bladder cancer cell lines |
| FGF23 | Chronic kidney disease, hypophosphatemic rickets | Knockout and transgenic mouse models |
| Klotho | Chronic kidney disease, aging | Klotho knockout mice |
| Ezrin | Regulation of NaPi-IIa; potential role in phosphate wasting | Point mutation (S249A) in renal cell lines |
Chronic Kidney Disease and Hyperphosphatemia
In chronic kidney disease (CKD), reduced kidney function leads to impaired phosphate excretion and hyperphosphatemia. Elevated FGF23 and PTH levels attempt to compensate by downregulating sodium-dependent phosphate transporters, but eventually fail, contributing to vascular calcification and cardiovascular disease. Targeting the negative regulation of phosphate transport is a therapeutic strategy in CKD.
Cancer: Bladder Cancer and Tumor Calcification
SLC34A2 (NaPi-IIb) is overexpressed in bladder cancer and is an independent prognostic indicator. Depletion of SLC34A2 suppresses tumor growth by decreasing c-Myc expression and transcriptional activity, linking phosphate transport to cancer cell proliferation. Additionally, tumor calcification can be influenced by phosphate transporters, as seen with tenofovir suppressing mineralization in osteoblasts.
Bone Disorders and Mineralization
Proper regulation of phosphate transport is essential for bone mineralization. Tenofovir disoproxil fumarate suppresses type II and III sodium-dependent phosphate transporters in osteoblasts, reducing mineralization. Dysregulation of FGF23-Klotho signaling leads to disorders like tumor-induced osteomalacia and hereditary hypophosphatemic rickets, where phosphate wasting occurs due to excessive negative regulation.
From negative regulation of sodium-dependent phosphate transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate sodium-dependent phosphate transport? | CRISPR knockout in renal or osteoblast cell lines, followed by phosphate uptake assay |
| What is the role of phosphorylation at a specific residue in transporter regulation? | Point mutation knock-in (e.g., S249A in ezrin) |
| How does a disease-associated mutation affect transporter function? | Knock-in of patient mutations in SLC34A1 or SLC34A3 |
| Can overexpression of SLC34A2 drive tumor growth? | Overexpression in bladder cancer cell lines |
| What are the downstream effectors of FGF23 signaling? | Knockout of FGF23 or Klotho in mouse models |
| How does a drug affect phosphate transporter expression? | Treatment of primary osteoblasts with tenofovir, followed by qPCR and Western blot |
How to Study the negative regulation of sodium-dependent phosphate transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive phosphate uptake assay | Sodium-dependent phosphate transport activity | Functional validation of negative regulators |
| Western blot | Protein abundance of transporters | Assessing downregulation by hormones or drugs |
| qRT-PCR | mRNA levels of transporters | Transcriptional regulation |
| Immunofluorescence | Subcellular localization of transporters | Endocytosis and trafficking |
| Co-immunoprecipitation | Protein-protein interactions | Identifying ezrin-transporter complexes |
| CRISPR knockout | Gene function | Discovering novel regulators |
| Phos-tag gel | Phosphorylation status of proteins | Studying ezrin phosphorylation |
| RNA-seq | Global gene expression changes | Identifying pathways affected by FGF23 |
Transport Assays
Sodium-dependent phosphate transport activity is typically measured using radioactive 32P or fluorescent phosphate analogs in cell culture models. For example, uptake assays in opossum kidney cells have been used to study PTH-mediated downregulation of NaPi-IIa. These assays provide direct functional readouts of negative regulation.
Protein Interaction and Localization Studies
Co-immunoprecipitation, GST pull-down, and proximity ligation assays can identify interactions between transporters and regulatory proteins like ezrin. Immunofluorescence and subcellular fractionation reveal changes in transporter localization from the plasma membrane to intracellular compartments upon negative regulation.
Transcriptomic and Proteomic Profiling
RNA-seq and quantitative proteomics can quantify changes in transporter mRNA and protein levels following stimuli such as tenofovir treatment or FGF23 exposure. These methods help distinguish transcriptional from post-translational regulation.
CRISPR-Based Functional Genomics
CRISPR knockout screens can identify novel genes that negatively regulate sodium-dependent phosphate transport. For instance, knocking out candidate genes in renal cells followed by phosphate uptake assays can reveal regulators. Point mutations can be introduced to study specific phosphorylation sites, as with ezrin S249.
How CRISPR Can Be Used to Study GO:2000119 negative regulation of sodium-dependent phosphate transport
Knockout
CRISPR knockout of genes such as SLC34A1, SLC34A2, or ezrin can abolish their function and reveal their role in negative regulation of phosphate transport. For example, knocking out ezrin in renal cells would prevent PTH-mediated downregulation of NaPi-IIa, leading to increased phosphate uptake. Knockout models are essential for causal inference.
Point Mutation
Introducing point mutations, such as S249A in ezrin, allows researchers to study the effect of specific phosphorylation sites on transporter regulation. This approach can pinpoint critical residues required for negative regulation. Point mutation knock-in models are valuable for mimicking human genetic variants.
Knock-in
Knock-in of disease-associated mutations in SLC34A1 or SLC34A3 can model phosphate wasting disorders. For instance, knocking in a mutation that impairs transporter internalization would lead to hyperphosphatemia. Knock-in also enables tagging of endogenous proteins for live-cell imaging.
Overexpression
Overexpression of SLC34A2 in bladder cancer cells has been shown to promote tumor growth via c-Myc, demonstrating the oncogenic potential of dysregulated phosphate transport. Overexpression models help identify gain-of-function effects and therapeutic targets.
How EDITGENE Supports negative regulation of sodium-dependent phosphate transport Research
Researchers studying negative regulation of sodium-dependent phosphate transport-related genes often need to determine whether a candidate gene is causally involved in transporter downregulation, and whether specific mutations alter this process. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of sodium-dependent phosphate transport research.
Frequently Asked Questions About negative regulation of sodium-dependent phosphate transport
What is GO:2000119?
GO:2000119 is a Gene Ontology term for negative regulation of sodium-dependent phosphate transport, describing any process that reduces the frequency, rate or extent of sodium-coupled phosphate uptake.
What genes are involved in negative regulation of sodium-dependent phosphate transport?
Key genes include SLC34A1, SLC34A2, SLC34A3, SLC20A1, SLC20A2, PTH, FGF23, Klotho, and ezrin.
How does PTH downregulate sodium-dependent phosphate transport?
PTH triggers phosphorylation of ezrin at S249 and internalization of NaPi-IIa via membrane microdomains, reducing phosphate uptake.
What diseases are associated with dysregulated sodium-dependent phosphate transport?
Chronic kidney disease, hyperphosphatemia, tumor calcification, bladder cancer, and hereditary hypophosphatemic rickets.
What is the role of FGF23 in phosphate transport?
FGF23, with its co-receptor Klotho, reduces renal phosphate reabsorption by downregulating NaPi-IIa and NaPi-IIc.
How can I study negative regulation of sodium-dependent phosphate transport?
Use CRISPR knockout, point mutation knock-in, overexpression models, phosphate uptake assays, and RNA-seq.
What is SLC34A2 and why is it important?
SLC34A2 encodes NaPi-IIb, a sodium-dependent phosphate transporter; its overexpression is linked to bladder cancer progression.
Does tenofovir affect phosphate transporters?
Yes, tenofovir disoproxil fumarate suppresses type II and III sodium-dependent phosphate transporters in osteoblasts, reducing mineralization.
What are the synonyms for GO:2000119?
There are no synonyms listed for GO:2000119 in QuickGO.
Which model systems are best for studying this process?
Renal proximal tubule cell lines (e.g., opossum kidney cells), osteoblasts, and knockout mouse models are commonly used.
Conclusion
Negative regulation of sodium-dependent phosphate transport (GO:2000119) is a critical biological process for maintaining phosphate homeostasis, with profound implications for kidney disease, cancer, and bone disorders. Understanding its molecular mechanisms, from hormonal signaling to transporter endocytosis, offers therapeutic opportunities. EDITGENE's CRISPR services empower researchers to dissect this pathway with precision, accelerating discoveries in phosphate-related pathologies.
References
- 1. Yamada F et al.. 2013. Role of serine 249 of ezrin in the regulation of sodium-dependent phosphate transporter NaPi-IIa activity in renal proximal tubular cells.. J Med Invest 60(1-2):27-34 PMID: 23614908
- 2. Barbieri AM et al.. 2018. Suppressive effects of tenofovir disoproxil fumarate, an antiretroviral prodrug, on mineralization and type II and type III sodium-dependent phosphate transporters expression in primary human osteoblasts.. J Cell Biochem 119(6):4855-4866 PMID: 29363823
- 3. Takeda E et al.. 2004. Inorganic phosphate homeostasis and the role of dietary phosphorus.. J Cell Mol Med 8(2):191-200 PMID: 15256067
- 4. Ohnishi M et al.. 2013. Osteo-renal cross-talk and phosphate metabolism by the FGF23-Klotho system.. Contrib Nephrol 180:1-13 PMID: 23652546
- 5. Frei P et al.. 2005. Identification and localization of sodium-phosphate cotransporters in hepatocytes and cholangiocytes of rat liver.. Am J Physiol Gastrointest Liver Physiol 288(4):G771-8 PMID: 15564340
- 6. Nashiki K et al.. 2005. Role of membrane microdomains in PTH-mediated down-regulation of NaPi-IIa in opossum kidney cells.. Kidney Int 68(3):1137-47 PMID: 16105044
- 7. Gamba G. 2001. Alternative splicing and diversity of renal transporters.. Am J Physiol Renal Physiol 281(5):F781-94 PMID: 11592935
- 8. Ye W et al.. 2017. Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity.. Cell Death Dis 8(2):e2581 PMID: 28151475
